

Confirmed Speakers

Keynote Speakers

Sequence-Based Design of RNA-Targeted Small Molecules (KL01)

Prof. Matthew DISNEY
(UF SCRIPPS, Jupiter, United States)

Reimagining Druggability using Chemoproteomic Platforms (KL03)

Prof. Daniel NOMURA
(UC BERKELEY, Berkeley, United States)

How Ligand-Binding Biophysics can Advance a Small-Molecule Neuroscience Portfolio (KL02)

Dr Laura SILVIAN
(BIOGEN, Cambridge, United States)

Session 1: EMERGING TECHNOLOGIES - NEW BIOPHYSICAL APPROACHES FOR MEASURING MOLECULAR INTERACTIONS

Kinetic Characterization of Ligand and Antibody Binding to Cell Surface Expressed CCRL2 Using Surface Plasmon Resonance Microscopy (SPRM) (IL01)

Dr Jonathan BROOKS
(PFIZER, Cambridge, United States)

High-Throughput Protein Analysis and Binding Assays Enabled by IR-MALDESI-MS (IL02)

Dr Nathaniel ELSER
(ABBVIE INC., North Chicago, United States)

Single-Molecule Analysis of Drug-Target Interactions Using a Molecular Forceps (OC01 - virtual presentation)

Prof. Terence STRICK
(ECOLE NORMALE SUPÉRIEURE, Paris, France)

NMR Reporter Assays for the Quantification of Weak-Affinity Receptor–Ligand Interactions (OC02)

Dr Reto WALSER
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom)

Session 2: COVALENT DRUG DISCOVERY

Discovery of the KRAS G12C Covalent Drug Adagrasib and Beyond (OC04)

Dr Robin GUNN
(MIRATI THERAPEUTICS, San Diego, United States)

In-Cell Covalent Inhibitors Discovery (IL04)

Dr Brent MARTIN
(SCORPION THERAPEUTICS, Boston, United States)

Covalent Screening and Hit Characterization Methods for Efficient Covalent Drug Discovery (OC03)

Dr Mela MULVIHILL
(GENENTECH, INC., South San Francisco, United States)

Developing Covalent Small Molecules for Protein Targets from Kinases to Transcription Factors (IL03)

Dr Tinghu ZHANG
(STANFORD, Stanford, United States)

Session 3: HYBRID METHODS AND TECHNIQUE COMBINATIONS

Identification and Characterization of Modulators of DEAH-Box Helicase DHX9 (OC08)

Confirmed Speakers

Dr Ann BORIACK-SJODIN
(ACCENT THERAPEUTICS, Lexington, United States)

HDX-MS Use as a Complementary Technique to X-ray Crystallography and Cryo-EM to Better Understand Small Molecule Binding Events (OC06)

Dr Fabrice CIESIELSKI
(NOVALIX, Illkirch, France)

Drug Discovery for the Oncogenic Protein KRAS on a Model Membrane (OC05)

Dr Fenneke KLEINJAN
(UHN, Toronto, Canada)

***Leishmania* Translation Initiation Factor IF4E: a Potential Target for Antiparasitic Drug Development (IL05)**

Dr Mélissa LÉGER-ABRAHAM
(BLAVATNIK INSTITUTE | HARVARD MEDICAL SCHOOL, Boston, United States)

Biophysical Characterization of Allosteric Cooperativity in PRMT5 (OC07)

Prof. Till MAURER
(IDEAYA BIOSCIENCES, South San Francisco, United States)

Integration of Biophysics and Simulation to Drive Drug Discovery (IL06)

Dr Holly SOUTTER
(BROAD INSTITUTE, Cambridge, United States)

Session 4: BIOPHYSICAL ASSAYS FOR PROTACS AND MOLECULAR GLUES

A Covalent BTK Ternary Complex Compatible with Targeted Protein Degradation (IL08)

Dr Matthew CALABRESE
(PFIZER, Groton, United States)

An Integrated Biophysical Approach to Discover Ligands for a Novel E3 Ligase (IL07)

Dr Nichole O'CONNELL
(KYMERA THERAPEUTICS, Watertown, United States)

Capturing the Flexibility of CRBN Protacs with Cryo-EM (OC10)

Dr Daniel PETER
(BOEHRINGER INGELHEIM, Vienna, Austria)

Targeted MDM2 Degradation Reveals a new Vulnerability for P53-Inactivated Triple Negative Breast Cancer (OC09)

Dr Joseph SALVINO
(THE WISTAR INSTITUTE, Philadelphia, United States)

Session 5: SMALL MOLECULES TARGETING RNA / UNDERSTANDING SMALL-MOLECULE SELECTIVITY TOWARDS RNA

A Structure-based Approach to Discovering RNA-targeted Small Molecules (IL10)

Dr Elena MENICHELLI
(ARRAKIS THERAPEUTICS, Waltham, United States)

Exploring the Undiscovered Country of RNA as a Drug target — Finding Bioactive Ligands against XIST RNA with Affinity-selection MS Screening (IL09)

Dr Elliott B. NICKBARG
(MERCK & CO., INC., Boston, United States)